التفاصيل البيبلوغرافية
| العنوان: |
Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. |
| المؤلفون: |
Backhaus, Donata1 (AUTHOR), Jentzsch, Madlen1 (AUTHOR), Bischof, Lara1 (AUTHOR) donata.backhaus@medizin.uni-leipzig.de, Brauer, Dominic1 (AUTHOR), Wilhelm, Christina1 (AUTHOR), Schulz, Julia1 (AUTHOR), Franke, Georg-Nikolaus1 (AUTHOR), Pönisch, Wolfram1 (AUTHOR), Vucinic, Vladan1 (AUTHOR), Platzbecker, Uwe1 (AUTHOR), Schwind, Sebastian1 (AUTHOR) Sebastian.Schwind@medizin.uni-leipzig.de |
| المصدر: |
Cancers. Nov2021, Vol. 13 Issue 22, p5679. 1p. |
| مصطلحات موضوعية: |
*GENETIC mutation, *CARCINOGENESIS, *AGE distribution, *CANCER relapse, *ACUTE myeloid leukemia, *RETROSPECTIVE studies, *RISK assessment, *TREATMENT effectiveness, *CANCER patients, *JANUS kinases, *COMPARATIVE studies, *CHROMOSOME abnormalities, *DESCRIPTIVE statistics, *LEUKOCYTE count, *DISEASE susceptibility, *HEMATOPOIETIC stem cell transplantation, *TUMOR markers, *OXIDOREDUCTASES, *CYTOGENETICS, *TRANSPLANTATION of organs, tissues, etc., *LONGITUDINAL method, *DISEASE risk factors, *SYMPTOMS, *EVALUATION |
| مستخلص: |
Simple Summary: Trisomy 8 is the most common numerical chromosome aberration in acute myeloid leukemia (AML). Although this AML type is often consolidated applying allogeneic hematopoietic stem cell transplantations (HSCT), detailed analyses of outcomes after HSCT are lacking. The purpose of this manuscript is to analyze biological and clinical features of patients with this cytogenetic aberration in the context of significant risk factors, including the ELN2017 risk stratification and measurable residual disease markers at HSCT. Our data provides evidence on the clinical disease courses and may aid in informed decisions on treatment and outcome prediction of trisomy 8 AML patients undergoing allogeneic HSCT. Background: For most patients with acute myeloid leukemia (AML) harboring a trisomy 8 an allogeneic hematopoietic stem cell transplantation (HSCT) is a suitable and recommended consolidation therapy. However, comparative outcome analyses between patients with and without trisomy 8 undergoing allogeneic HSCT have not been performed so far. Methods: We retrospectively analyzed clinical features, outcomes, and measurable residual disease (MRD) of 659 AML (12%, n = 81, with a trisomy 8) patients subjected to allogeneic HSCT as a consolidation therapy. Results: The presence of a trisomy 8 associated with a trend for higher age at diagnosis, AML of secondary origin, lower white blood cell counts at diagnosis, worse ELN2017 genetic risk, wild-type NPM1, and mutated IDH1/2 and JAK2. Outcomes after allogeneic HSCT in the entire cohort did not differ between patients with a sole trisomy 8, trisomy 8 with additional cytogenetic aberrations or without a trisomy 8. A trisomy 8 did not affect outcomes within the three ELN2017 risk groups. In accordance with findings in unselected patient cohorts, persistent MRD at allogeneic HSCT in patients with a trisomy 8 identified individuals with a higher risk of relapse following allogeneic HSCT. Conclusions: Outcomes of trisomy 8 patients after allogeneic HSCT did not compare unfavorably to that of other AML patients following allogeneic HSCT. Rather than the presence or absence of a trisomy 8, additional genetic aberrations and MRD at HSCT define outcome differences and aid in informed treatment decisions. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder